XOMA Acquires Royalty Rights to Five Hematology Candidates
08 Abril 2019 - 7:00AM
XOMA Corporation (NASDAQ: XOMA) announced today it has agreed to
acquire the rights to potential royalty payments and a portion of
the potential milestone payments associated with five hematology
assets from Aronora, Inc. Three of the assets are
anti-thrombotic candidates that are covered by a collaboration with
Bayer, a global leader in hematology therapeutics. Two of the
collaboration assets are in early to mid-stages of development and
the third is a Phase 2 candidate that is subject to an
option. In addition, XOMA agreed to acquire the rights to
potential royalty payments and a portion of the potential upfront
and milestone payments associated with two unpartnered hematology
programs from Aronora.
“The transaction diversifies XOMA’s royalty interest portfolio
by expanding into hematology indications, and these innovative
anti-thrombotic candidates have the potential to address very large
market opportunities. The fact that three assets are part of
an ongoing collaboration between Aronora and Bayer, a company for
whom we have tremendous respect, strengthens our belief in the
potential of these therapies to address significant unmet medical
needs,” said Jim Neal, Chief Executive Officer at XOMA.
“These assets possess the characteristics we have established
for our royalty aggregator business model: outstanding development
partner, mid-stage to early clinical stage of development,
important therapeutic categories, and sizable potential royalty
opportunities. Aronora’s expertise in hematology, with an
advanced focus on anti-thrombotic monoclonal antibodies, intrigued
our team.”
The five royalty interest assets XOMA acquired from Aronora
are:
- Three Bayer collaboration monoclonal antibody (mAb) programs
targeting factor XI/XIa: BAY1213790 in Phase 2 clinical
development; BAY1831865 in early clinical development; and
Aronora’s AB023 (xisomab 3G3) in Phase 2 development; and,
- Two proprietary hematology programs at Phase 1 and preclinical
stage: AB002, a thrombin analog, and AB054, a factor XII mAb,
positioned for acute cardiovascular events, medical device
associated clots, and/or inflammation.
Under the terms of the agreement, XOMA will make an initial $6
million payment subject to closing conditions defined in the
agreement. XOMA will make an additional payment of up to $3
million to Aronora upon fulfillment of certain other
conditions. In return, XOMA will receive, on average, low
single-digit royalties on future sales of these five products and
10 percent of the milestones associated with each of the
assets. In addition, XOMA could pay Aronora sales-based
milestones on each asset if XOMA’s royalty receipts related to each
program exceed certain thresholds. XOMA expects this
transaction to close within the next 90 days.
About XOMA CorporationXOMA has built a
significant portfolio of products that are licensed to and being
developed by other biotechnology and pharmaceutical companies.
The Company’s portfolio of partner-funded programs spans
multiple stages of the drug development process and across various
therapeutic areas. Many of these licenses are the result of
XOMA’s pioneering efforts in the discovery and development of
antibody therapeutics. The Company’s royalty-aggregator
business model includes acquiring additional licenses to
partner-funded programs. For more information, visit
www.xoma.com.
About Aronora Inc.Aronora Inc. is a
translational biotechnology company engaged in the commercial
development of proprietary biologic therapeutics, including
recombinant monoclonal antibodies and enzymes. For more
information, please visit www.aronorabio.com.
Forward-Looking StatementsCertain statements
contained in this press release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including
statements regarding the potential of XOMA’s portfolio of partnered
programs and licensed technologies to generate royalty proceeds
over time and create potential cash flow, including from potential
milestone and royalty payments associated with hematology programs
of Aronora. These statements are based on assumptions that
may not prove accurate, and actual results could differ materially
from those anticipated due to certain risks inherent in the
biotechnology industry, including those related to the fact that we
may not receive any significant royalty or milestone payments from
Aronora’s assets, product candidates subject to out-license
agreements are still being developed, and our licensees may require
substantial funds to continue development which may not be
available; we do not know whether there will be, or will continue
to be, a viable market for the products in which we have an
ownership or royalty interest; we may not be successful in entering
into out-license agreements for our product candidates; if our
therapeutic product candidates do not receive regulatory approval,
our third-party licensees will not be able to manufacture and
market them. Other potential risks to XOMA meeting these
expectations are described in more detail in XOMA's most recent
annual report on Form 10-K, in subsequent quarterly reports on Form
10-Q and in other SEC filings. Consider such risks carefully
when considering XOMA's prospects. Any forward-looking
statement in this press release represents XOMA's views only as of
the date of this press release and should not be relied upon as
representing its views as of any subsequent date. XOMA
disclaims any obligation to update any forward-looking statement,
except as required by applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press
release refer strictly to milestone and/or royalty rights
associated with a basket of drug products in development. Any
references to “assets” in this press release refer strictly to
milestone and/or royalty rights associated with individual drug
products in development.
Investor contact:Juliane
SnowdenOratorium Group, LLC+1
646-438-9754jsnowden@oratoriumgroup.com
Media contact:Kathy VincentKV
Consulting & Management+1
310-403-8951kathy@kathyvincent.com
XOMA (NASDAQ:XOMA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
XOMA (NASDAQ:XOMA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024